Clinical Trials Logo

Clinical Trial Summary

The purpose of this survey is to evaluate the long-term safety and efficacy of leuprorelin acetate injection kit 11.25 mg in patients with spinal and bulbar muscular atrophy (SBMA) in the routine clinical setting.


Clinical Trial Description

The drug being tested in this survey is called leuprorelin acetate injection kit 11.25 mg. This injection kit is being tested to treat people who have SBMA. This survey is an observational (non-interventional) study and will look at the long-term safety and efficacy of the leuprorelin acetate injection kit 11.25 mg in the routine clinical setting. The planned number of observed patients will be approximately 300. This multi-center observational trial will be conducted in Japan. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03555578
Study type Observational
Source Takeda
Contact Takeda Study Registration Call Center
Phone +1-877-825-3327
Email medicalinformation@tpna.com
Status Recruiting
Phase
Start date November 2, 2017
Completion date August 31, 2025

See also
  Status Clinical Trial Phase
Recruiting NCT04944940 - Clinical, Molecular and Imaging Biomarkers in Spinal and Bulbar Muscular Atrophy (SBMA)
Completed NCT00303446 - Dutasteride to Treat Spinal and Bulbar Muscular Atrophy (SBMA) Phase 2
Recruiting NCT06411912 - A Study of NIDO-361 in Patients With SBMA Phase 2
Completed NCT02156141 - High Intensity Training in Patients With Spinal and Bulbar Muscular Atrophy N/A
Completed NCT02024932 - Safety, Tolerability, and Efficacy of BVS857 in Patients With Spinal and Bulbar Muscular Atrophy Phase 2
Active, not recruiting NCT05517603 - A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Of AJ201 In Patients Phase 1/Phase 2
Recruiting NCT06169046 - A Placebo-controlled Study of Clenbuterol in Spinal and Bulbar Muscular Atrophy Phase 2